Pharnext SA represents a commitment to innovation and excellence in the biopharmaceutical industry. With a strong focus on research and development, the company strives to provide groundbreaking solutions to medical challenges. Pharnext prioritizes the improvement of patient lives through its unique business model, which combines conventional pharmaceutical approaches with advanced big data analytics. By leveraging cutting-edge technology and collaboration with industry experts, Pharnext aims to accelerate the discovery and development of new treatments for various diseases. The company's dedication to scientific advancement and a patient-centric approach truly sets Pharnext SA apart in the biopharmaceutical landscape.

Pharnext SA is primarily present in France.

Pharnext SA, a leading pharmaceutical company, has achieved several significant milestones. One notable achievement is the successful completion of its Phase 3 clinical trial for PXT3003, a potential treatment for Charcot-Marie-Tooth disease type 1A (CMT1A). The positive results obtained during this trial have opened doors for Pharnext SA to further advance its development and seek regulatory approval. Moreover, the company has formed strategic collaborations with renowned institutions and industry partners to accelerate research and development efforts. Pharnext SA's commitment to innovation and dedication to addressing critical medical needs reaffirm its position as a prominent player in the pharmaceutical industry.

Pharnext SA is a renowned biopharmaceutical company, specializing in the development and commercialization of innovative drugs. Established in 2007, Pharnext SA has rapidly emerged as a key player in the healthcare industry. Their dedicated team of experts combines cutting-edge science with advanced technologies to create effective treatments for a wide range of diseases. With a strong focus on neurological disorders and orphan diseases, Pharnext SA diligently works toward improving patients' lives and addressing unmet medical needs. Through strategic collaborations and extensive research, the company aims to revolutionize the healthcare landscape by delivering breakthrough therapies and making a lasting impact on global health.

The main competitors of Pharnext SA in the market include pharmaceutical companies such as Novartis, Pfizer, and Sanofi. These companies also operate in the biotechnology sector, focusing on innovation and drug development. With Pharnext SA's expertise in the development of innovative treatments, it competes directly with these industry giants in establishing its presence and gaining market share. Despite the competition, Pharnext SA continues to differentiate itself by leveraging its unique approach to drug discovery and strategic collaborations, enabling it to create value for patients and stakeholders.

Pharnext SA is primarily active in the pharmaceutical industry.

The business model of Pharnext SA is focused on biopharmaceutical research and development. Pharnext conducts innovative research to identify and develop new drug combinations for various medical conditions. By leveraging its proprietary technology platform, Pharnext aims to accelerate the discovery and development of effective treatments. The company collaborates with partners in academia, biotech, and pharmaceutical industries to advance its research programs. With a strong emphasis on precision medicine, Pharnext aims to improve patient outcomes by targeting multiple pathways and addressing complex diseases. Through its holistic approach and extensive expertise, Pharnext strives to deliver high-value therapeutic solutions to improve the lives of patients.

Rasio P/E Pharnext adalah -0,00.

Rasio KUV dari Pharnext adalah 0,00.

Skor Kualitas AlleAktien untuk Pharnext adalah 5/10.

Omset diharapkan Pharnext adalah 9,22 Juta. EUR.

Laba diharapkan Pharnext adalah -582,38 miliar EUR.

Pharnext SA is a biopharmaceutical company based in France that focuses on developing therapies for the treatment of rare diseases. They use a patented technology platform called Pleotherapy to combine multiple approved drugs and create new treatments with improved safety, efficacy, and duration. Their business activities are divided into research and development, marketing and sales, and clinical development. They aim to provide innovative and effective therapeutic treatments that reduce healthcare costs and benefit patients. Overall, Pharnext's business model is innovative and shows potential for investors and the healthcare sector.

Pharnext membayarkan dividen sebesar 0 EUR yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Pharnext saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Pharnext adalah FR0011191287.

WKN dari Pharnext adalah A2AM02.

Ticker dari Pharnext adalah ALPHA.PA.

Dalam 12 bulan terakhir, Pharnext membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, Pharnext diperkirakan akan membayar dividen sebesar 0 EUR.

Imbal hasil dividen dari Pharnext saat ini adalah .

Pharnext membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Pharnext membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 EUR. Ini setara dengan yield dividen sebesar 0 %.

Pharnext dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Pharnext tanggal 10/11/2024 sejumlah 0 EUR, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 10/11/2024.

Pembayaran dividen terakhir dilakukan pada 10/11/2024.

Pada tahun 2023, Pharnext 0 EUR telah dibayarkan sebagai dividen.

Dividen dari Pharnext dibayarkan dalam EUR.